1. Scrip
  2. >>Advanced Therapies

CG Oncology Is Building A Best-In-Class Profile In NMIBC

Cretostimogene Phase III Data Look Competitive

 
• By Joseph Haas

The biotech’s Phase III data with an oncolytic immunotherapy for non-muscle invasive bladder cancer shows high complete response rates, duration of response and good safety/tolerability.

CG Oncology's Phase III data look competitive in high-risk bladder cancer (Shutterstock)

CG Oncology believes that the Phase III data for its oncolytic immunotherapy for bladder cancer show that cretostimogene grenadenorepvec can spare patients bladder surgery, and analysts said the data could position it as a best-in-class therapy for high-risk non-muscle invasive bladder cancer (NMIBC) compared to a competing Phase III candidate from Johnson & Johnson, as well as Merck & Co.’s Keytruda (pembrolizumab).

Key Takeaways
  • CG Oncology sees additional Phase III data for cretostimogene as bolstering its case that the oncolytic immunotherapy is a best-in-class therapy for non-muscle invasive bladder...

The company presented data from the Phase III BOND-003 monotherapy trial on 5 December at the Society of Urologic Oncology annual meeting, showing that 74.5% (82/110) of patients achieved a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Advanced Therapies

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.